Biomarkers, Pathways, and Targeted Therapies®
Two HER2-targeting regimens anchored by T-DM1 (ado-trastuzumab emtansine; Kadcyla) failed to outperform the standard strategy in women with previously untreated advanced HER2-positive breast cancer in the MARIANNE trial, dealing a blow to efforts to move the drug into frontline settings.
Most Popular Right Now
Precision Medicine in Oncology®
Precision Medicine—An Inevitable (Though Challenging) Goal!Andre Goy, MD, writes about implementing precision medicine, which requires a global effort from clinicians, insurance providers, government regulators, and the pharmaceutical industry.
Read more >>>